ABBOTT RECEIVES CE MARK FOR ITS GROUNDBREAKING ASSERT-IQ™ INSERTABLE CARDIAC MONITOR, EXPANDING AVAILABILITY OF LONG-TERM MONITORING FOR IRREGULAR HEART RHYTHMS Posted on March 25th, 2024 by LEADconnection Post navigation Previous: Biotronik introduces “first” complete system for LBBAPNext: MicroPort® CRM Announces the First Implantation of ALIZEA Bluetooth Pacemaker System in the United States
Cardiovascular Infection on the Rise: New Multisociety Statement Defines Appropriate Use of PET/CT and SPECT/CT for Evaluation Posted on March 11th, 2024 by LEADconnection Post navigation Previous: Micra Leadless Pacemaker Performs Well Through 5 YearsNext: Impact of the COVID-19 pandemic on implantation of cardiac implantable electronic devices and remote monitoring activations.
MicroPort® CRM announces the launch of GALI SonR CRT-D and NAVIGO 4LV left ventricular pacing leads in Japan Posted on February 18th, 2024 by LEADconnection Post navigation Previous: Campylobacter coli enteritis associated with Campylobacter fetus bacteremia, spondylodiscitis, and late CIED-related endocarditis, a case report.Next: CMS Mandate for Shared Decision-Making Didn’t Affect ICD Use
